The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 3, 2013, Pages 237-242

  Ferrara, Filippo ^a   Meli, Francesco ^a   Raimondi, Francesco ^a   Montalto, Salvatore ^a   Cospite, Valentina ^a   Novo, Giuseppina ^a   Novo, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

4G 5G polymorphism; calf venous thrombosis; extension of thrombotic lesion

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL SURGERY; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; UROLOGIC SURGERY; VEIN THROMBOSIS;

AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PROMOTER REGIONS, GENETIC; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84875857575     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328359f618     Document Type: Article

References (55)

1. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thrombotic disease. Sem Thromb Hemost 1990; 16:207-216. (Pubitemid 20289927)
2. Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator mediated fibrin dissolution. J Biol Chem 1992; 267:17128-17135.
3. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11:183-190.
4. Zietz B, Buechler C, Drobnik W, Herfarth H, Scholmerich J, Schaffler A. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack association with PAI-! plasma levels. Endocrin Res 2004; 30:443-453. (Pubitemid 39453091)
5. Leander K, Wiman B, Hallqvist J, Sten-Linder M, de Faire U. Stocholm Heart Epidemiology Program. PAI-1 level and PAI-1 4G/5G polymorphism in relatioship to risk of nonfatal myocardial infarction: results from the Srockholm Heart Ee idemiology program (SHEEP). Thromb Haemost 2003; 89:1064-1071. (Pubitemid 36798159)
6. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9. (Pubitemid 17083665)
7. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-1168. (Pubitemid 23137110)
8. Boekholdt SM, Bjisterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104:3063-3073.
9. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Sae YH. 4G/5G polymophism of the plasminogen activator inhibitor-1 gene and insertion/ deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001; 11:294-299.
10. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 2002; 9:131-137. (Pubitemid 34553593)
11. Vergouwen MD, Frijins CJ, Roos YB, Rinkel GJ, Baas F, Vermeulen S. Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increase the occurence of cerebral ischemia after aneurysma subarachnoid hemorrhage. Stroke 2004; 35:1280- 1283. (Pubitemid 38697443)
12. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J 2003; 116:1707-1710. (Pubitemid 38008245)
13. Hoekstra T, Gelejinse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk stroke in elderly. Stroke 2003; 34:2282-2288.
14. Junker R, Nabavi DG, Wolff E, Ludemann P, Npowak-Gottl U, Kase M, et al. Plasminogen activator inhibithor-1 4G/5G genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost 1998; 80:706-707. (Pubitemid 28479367)
15. Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR. A novel G/A and 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 1996; 84:431-443. (Pubitemid 27033603)
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with 4G75 g polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95:59-62. (Pubitemid 27029943)
17. Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, et al. The role of the t-PA I/D and PAI-1 4G/5G plymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000; 99:223-230. (Pubitemid 30608700)
18. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous thromboembolism in mice transgenic for the plasminogen activator inhibitor -1 gene. Nature 1990; 346:74-76.
19. Visanji JM, Seargent J, Tahri D, Croft SA, Makris M, Preston FE, et al. Influence of the: 675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. Br J Haematol 2000; 110:135-138. (Pubitemid 30625602)
20. Barcellona D, Fenu L, Cauli C, Pisu G, Marongiu F. Allele 4G og gene PAI-1 associated with prothrombin mutation G20210A increase the risk for venous thrombosis. Thromb Haemost 2003; 90:1061-1064. (Pubitemid 38004424)
21. Forbes K, Stevenson AJ. The use of power Doppler ultrasound in the diagnosis of isolated deep venous thrombosis of the calf. Clin Radiol 1998; 53:752-754. (Pubitemid 28482360)
22. Gottlieb RH, Widjaja J, Tian L, Rubens DJ, Voci SL. Calf sonography for detecting deep venous thrombosis in symptomatic patients. Experience and review of the literature. J Clin Ultrasound 1999; 27:415-420. (Pubitemid 29449130)
23. Wells PS, Lensing AWA, Davidson BL, Prins MH, Hirsch J. Accuracy of ultrasound for the diagnosis of deep vein thrombosis in asymptomatic patients after orthopedic surgery. Ann Intern Med 1995; 22:47-53.
24. Davis R, Faulds D. Nadroparin calcium. A review of its pharmacologoical and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging 1997; 10:299-322.
25. Stricker H, Marchetti O, Haeberli A, Mombelli G. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thromb Haemost 1999; 82:1227-1231. (Pubitemid 29473782)
26. Egger b, Schmid SW, Naef M, Wildi S, Buchler MW. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1.990 general surgical patients. Dig Surg 2000; 17:602-609. (Pubitemid 32045996)
27. Laane DA, Grant PS. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95:1517-1532.
28. Sykes TC, Fegan C, Mosquera D. Thrombophilia polymorphisms and vascular disease. Mal Pathol 2000; 53:300-306.
29. Takeshita K, Yamamoto K, Ito M, Kondo T, Matsuhita T, Hirai M, et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murin model of aging, 'Klotho' mouse. Semin Thromb Hemost 2002; 28:545-554.
30. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism im the promoter of the plasminogen activator inhibitor-1 (PAI-1) egne respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739- 10745. (Pubitemid 23162248)
31. Juhan-Vague L, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57:67-72. (Pubitemid 17159602)
32. Segui R, Estelles A, Mira Y, Espana F, Villa P, Falco C, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genatic thrombophilic defects. Br J Haematol 2000; 111:122-128.
33. Chen YL, Zhang JX, Wang PX, Cui RZ, Zhao FM, Mao YM, et al. Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis. Zhonghua Yi Xue YI Chuan Za Zhi 2005; 22:624- 627.
34. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Di Bitonto R, Donati MB, Iacoviello L. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in italians: a model of gene-environment interaction. Thromb Haemost 1998; 79:354-358. (Pubitemid 28065884)
35. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P. Hamsten Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92:1851-1855.
36. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74:837-841.
37. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80:956-960. (Pubitemid 28556699)
38. Stegnar M, Uhrin P, Peternal P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor -1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79:975-979. (Pubitemid 28224735)
39. Masuda EM, Kessler DM, Kistner RL, Eklof B, Sato DT. The natural history of calf vein thrombosis: lysis of thrombi and development of reflux. J Vasc Surg 1998; 28:67-73.
40. Labropoulos N, Kang SS, Mansour MA, Giannoukas AD, Moutzouros V, Baker WH. Early thrombus remodelling of isolated calf deep vein thrombosis. Eur J Vasc Endovasc Surg 2002; 23:344-348. (Pubitemid 41079446)
41. Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness DE Jr. Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis. J Vasc Surg 1995; 22:558-567.
42. Killewich LA, Bedford GR, Beach KW, Strandness DE Jr. Spontaneous lysis of deep venous thrombi: rate and outcome. J Vasc Surg 1989; 9:89- 97. (Pubitemid 19046498)
43. Markel A, Meissner M, Manzo RA, Bergelin RO, Strandenss DE Jr. Deep venous thrombosis: rate of spontaneous lysis and thrombus extension. Int Angiol 2003; 22:376-382. (Pubitemid 38324806)
44. Sibbing D, von Beckerath O, von Beckerath N, Koch W, Mehilli J, Schwaiger M, et al. Plasminogen activator inhibitor-.1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul Fibrinolyis 2005; 16:511-515. (Pubitemid 41794946)
45. Ofili EO, Kern MJ, Vrain JA, Donohue TJ, Bach R, al-Joundi B, et al. Diffrential charactirization of blood flow, velocity, and vascular resistance between proximal and distal normal epicardial human coronary arteries: analysis by intracoronary Doppler spectral flow velocity. Am Heart J 1995; 130:37-46.
46. Doriot P, Dorsaz P, Dorsaz L, Chatelain P. Accuracy of coronary flow measurement performed by means of Doppler wires. Ultrasound Med Biol 2000; 26:221-228. (Pubitemid 30155651)
47. van Bemmelen PS, Bedford, Beack K, Strandness DE Jr. Functional status of the deep venous system after an episode of deep venous thrombosis. Ann Vasc Surg 1990; 4:455-459. (Pubitemid 20289257)
48. Baxter GM, Duffy P. Calf vein anatomy and flow. Implications for colour Doppler imaging. Clin Radiol 1993; 46:84-87.
49. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al., Investigators of the 'Duree Optimale du Traitement AntiVitamines K' (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103:2453-2460. (Pubitemid 32493371)
50. Schwarz T, Schmidt B, Beyer J, Schellong SM. Therapy of isolated calf vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis 2001; 12:597-599. (Pubitemid 33022526)
51. Buchanan MR, Liao P, Smith LJ, Ofosu FA. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors:importance of hepain cofactor II. Thromb Res 1994; 74:463-475. (Pubitemid 24173328)
52. Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabro A. Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res 1992; 18:189-195.
53. Vittoria A, Messa GL, Frigerio C, Celasco G, Auteri A. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. Int J Tissue React 1998; 10:261-266.
54. Grodzinska L, Konig E, Schror K. Defibrotide is equipotent to urokinase in stimulating arterial and venous thrombolysis. Pharmacol Res Commun 1987; 19:609-615. (Pubitemid 18042553)
55. Fumagalli G, sala C, Angelaccio E, Lombardo N, Clementi F. Thrombolytic activity of defibrotide: a morphometric evaluation in experimental venous thrombosis. Pharmacol Res 1989; 21:293-298. (Pubitemid 19150725)